Trade

with

pSivida Ltd
(NASDAQ: PSDV)
AdChoices
4.23
+0.16
+3.93%
After Hours :
-
-
-

Open

4.11

Previous Close

4.07

Volume (Avg)

268.02k (286.95k)

Day's Range

3.98-4.31

52Wk Range

2.28-5.45

Market Cap.

123.74M

Dividend Rate ( Yield )

-

Beta

1.57

Shares Outstanding

29.25M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 2.14M

    • Net Income

    • -11.90M

    • Market Cap.

    • 123.74M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -363.05

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.57

    • Forward P/E

    • -

    • Price/Sales

    • 29.85

    • Price/Book Value

    • 6.74

    • Price/Cash flow

    • -8.61

      • EBITDA

      • -11.04M

      • Return on Capital %

      • -59.08

      • Return on Equity %

      • -90.14

      • Return on Assets %

      • -59.08

      • Book Value/Share

      • 0.63

      • Shares Outstanding

      • 29.25M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 288.30

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -9.22

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 64.72

            • Pre-Tax Margin

            • -366.29

            • 13.77

            • Net Profit Margin

            • -363.05

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -287.70

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -283.20

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 9.87

              • 1.52

              • Quick Ratio

              • 9.61

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.42

              • 1.91

              • Book Value/Share

              • 0.63

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -7.28

                • 65.79

                • P/E Ratio 5-Year High

                • -14.05

                • 237.47

                • P/E Ratio 5-Year Low

                • -1.99

                • 19.71

                • Price/Sales Ratio

                • 26.46

                • 3.69

                • Price/Book Value

                • 5.96

                • 3.46

                • Price/Cash Flow Ratio

                • -8.61

                • 22.12

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -90.14

                        (-42.30)

                      • 7.86

                        (9.58)

                      • Return on Assets %

                        (5-Year Average)

                      • -59.08

                        (-28.10)

                      • 4.14

                        (5.54)

                      • Return on Capital %

                        (5-Year Average)

                      • -90.14

                        (-42.30)

                      • 5.59

                        (7.66)

                      • Income/Employee

                      • -

                      • 27.79k

                      • Inventory Turnover

                      • -

                      • 1.80

                      • Asset Turnover

                      • 0.16

                      • 0.38

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -12.03M
                      Operating Margin
                      -561.41
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -8.61
                      Ownership

                      Institutional Ownership

                      40.24%

                      Top 10 Institutions

                      38.11%

                      Mutual Fund Ownership

                      3.97%

                      Float

                      97.91%

                      5% / Insider Ownership

                      2.07%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Total Stock Mkt Idx

                      •  

                        395,834

                      • 0.51

                      • 1.35

                      • Vanguard Extended Market Index Fund

                      •  

                        219,058

                      • 0.00

                      • 0.75

                      • Bridgeway Ultra Small Company Market

                      •  

                        100,000

                      • 0.00

                      • 0.34

                      • iShares Micro-Cap

                      •  

                        84,803

                      • 0.00

                      • 0.27

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        82,313

                      • 0.00

                      • 0.28

                      • DFA U.S. Small Cap Portfolio

                      •  

                        36,454

                      • -8.34

                      • 0.12

                      • EB DL Non-SL Market Completion Fund

                      •  

                        27,418

                      • 763.02

                      • 0.09

                      • AQR Small Cap Momentum Fund

                      •  

                        26,700

                      • 0.00

                      • 0.09

                      • DFA U.S. Micro Cap Portfolio

                      •  

                        25,431

                      • 0.00

                      • 0.09

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • RA Capital Management, LLC

                      •  

                        2,555,659

                      • 0.00%

                      • 8.74

                      • Allan Gray Australia Pty Ltd

                      •  

                        2,475,483

                      • -3.30%

                      • 9.07

                      • North Run Capital, L P

                      •  

                        2,144,086

                      • -50.00%

                      • 7.33

                      • Pfizer Inc

                      •  

                        1,862,093

                      • 0.00%

                      • 6.91

                      • Vanguard Group, Inc.

                      •  

                        613,754

                      • 0.00%

                      • 2.10

                      • Great Point Partners LLC

                      •  

                        379,060

                      • +33.80%

                      • 1.30

                      • Morgan Stanley Investment Management Inc

                      •  

                        274,233

                      • 0.00%

                      • 0.94

                      • Fidelity Management and Research Company

                      •  

                        196,300

                      • -28.04%

                      • 0.67

                      • Dimensional Fund Advisors, Inc.

                      •  

                        162,523

                      • -8.90%

                      • 0.56

                      • JANE STREET GROUP, LLC

                      •  

                        144,318

                      • +6.38%

                      • 0.49

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Specific & Generic

                      Type

                      Distressed

                      Style

                      Small Core

                      pSivida Ltd was organized as a Delaware Corporation in March 2008. On June 19, 2008, it reincorporated from Western Australia to the United States. The Company develops tiny, sustained-release, drug delivery products designed to deli...morever drugs at a controlled and steady rate for months or years. It is focused on treatment of chronic diseases of the back of the eye utilizing its core technology platforms, Durasert™ and BioSilicon™. It currently has three approved products, as well as two current product candidates in clinical trials, use different generations of this technology system. It has developed three of the four sustained release devices for treatment of retinal diseases currently approved in the U.S. or the European Union (EU). ILUVIEN®, its recently approved product, is an injectable, sustai...morened-release micro-insert that provides treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies over a period of up to three years. ILUVIEN is being developed by its licensee Alimera Sciences, Inc. (Alimera). ILUVIEN has received marketing authorization in the United Kingdom, Austria, France, Germany and Portugal, and marketing authorization is pending in Italy and Spain. The International Diabetes Federation has estimated that approximately 19.0 million people have diabetes in the seven EU countries where ILUVIEN has received or been recommended for marketing authorization, of which Alimera has estimated that approximately 1.1 million people suffer from vision loss associated with DME. Alimera is also seeking marketing approval for ILUVIEN for DME in the U.S. Alimera has announced its intention to launch in France in the first quarter of 2014. It faces substantial competition for its products and product candidates. Its competitors and potential competitors are larger, better established and more experienced and have substantially more resources than the Company or its partners. Durasert™, Medidur™, Tethadur™ and BioSilicon™ are its trademarks.lessless

                      Key People

                      Dr. Paul Ashton

                      CEO/Director/President

                      Dr. David J. Mazzo, PhD

                      Chairman of the Board/Director

                      Leonard S. Ross

                      CFO/Chief Accounting Officer/Vice President, Divisional

                      Ms. Lori Freedman

                      General Counsel/Secretary/Vice President, Divisional

                      Mr. Peter G. Savas

                      Director

                      • pSivida Ltd

                      • 400 Pleasant Street

                      • Watertown, MA 02472

                      • USA.Map

                      • Phone: +1 617 926-5000

                      • Fax: +1 617 926-5050

                      • psivida.com

                      Incorporated

                      2008

                      Employees

                      25

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: